Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Share Finance Facility

15 Sep 2005 08:00

ReGen Therapeutics PLC15 September 2005 ReGen Therapeutics Plc Date 15 September 2005 Committed Share Finance Facility ReGen Therapeutics Plc ("ReGen" or the "Company") announces that on 14thSeptember 2005 it entered into an agreement with the Headstart Group of funds ("Headstart") under which Headstart will make available to the Company acommitted share finance facility of up to £2,000,000 (the "Headstart Facility"). Pursuant to the terms of the Headstart Facility, Headstart has agreed, whencalled upon by the Company, to subscribe for, or purchase, new ordinary sharesin the capital of the Company ("Ordinary Shares") to the value of up to, inaggregate, £2,000,000. The Headstart Facility is available at any time up to 3years from the date a Committed Share Finance Facility Agreement is entered intoby the Company and Headstart and can be drawn down by the Company in incrementsof up to £50,000. The subscription price for an Ordinary Share shall be equalto 95% of the lowest closing bid price of an Ordinary Share in the fifteentrading days following the date on which the Company notifies Headstart that itwishes to make a draw down under the Headstart Facility. In consideration for Headstart making available the Headstart Facility, theCompany has agreed to pay Headstart a one-off underwriting commission of £60,000payable by the issue of Ordinary Shares (on the basis of an agreed value perOrdinary Share of 1.35p, being the closing bid price on Wednesday 7th September2005). £30,000 of the underwriting commission was payable upon entering into theHeadstart Facility and the remaining £30,000 is payable on the first anniversarythereafter. Accordingly, application has been made for 2,222,222 OrdinaryShares to be admitted to trading on the AIM market. It is expected thatadmission to listing will become effective and that dealings in these shareswill commence on Tuesday 20th September 2005. In addition, the Company hasagreed, subject to shareholder approval, to issue warrants granting Headstartthe right to subscribe for up to 4,000,000 Ordinary Shares at a subscriptionprice of 1.65p per share, being a price equal to 110% of the closing bid priceof the Company's shares on 13th September 2005. Such warrants will beexercisable at any time on or before 14th September 2008. As the issue of theWarrants is subject to shareholder approval, ReGen will shortly send toshareholders a circular containing a notice convening an extraordinary generalmeeting of the Company (the "Circular") for 10.00 a.m. on 10 October 2005 (the "EGM") containing resolutions to, inter alia, approve the issue of the Warrants. Copies of the Circular will be available, for collection only, free of charge tothe public, from the Company, Suite 406, Langham House, 29-30 Margaret Street,London W1W 8SA during normal office hours on any day (Saturdays, Sundaysexcepted) from 19 September 2005 until 14 October 2005. - For further information, please contact:Andrew MarshallMarshall Robinson RoeTel No 020 7960 6007 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
20th Oct 20212:29 pmRNSScheme of arrangement
20th Oct 20212:00 pmRNSPrice Monitoring Extension
20th Oct 20217:00 amRNSDirector/PDMR Shareholding
19th Oct 20212:01 pmRNSCapital Reorganisation
6th Oct 20213:19 pmRNSDirector/PDMR Shareholding
5th Oct 20217:00 amRNSDirector/PDMR Dealing
4th Oct 20218:06 amRNSPDMR Dealing
28th Sep 20217:00 amRNSDirector/PDMR Shareholding
27th Sep 20215:16 pmRNSResult of Meeting
27th Sep 20215:11 pmRNSResult of Meeting
24th Sep 20215:49 pmRNSHalf-year Report
20th Sep 202111:05 amRNSSecond Price Monitoring Extn
20th Sep 202111:00 amRNSPrice Monitoring Extension
20th Sep 20219:05 amRNSSecond Price Monitoring Extn
20th Sep 20219:00 amRNSPrice Monitoring Extension
7th Sep 20216:00 pmRNSChange of Registered Office
7th Sep 20217:00 amRNSTLSA to Host Call to Discuss Exclusive License
3rd Sep 20215:00 pmRNSPosting of Scheme Document and Notice of Meetings
3rd Sep 20217:00 amRNSPosting of Scheme Document and Notice of Meetings
2nd Sep 202111:05 amRNSSecond Price Monitoring Extn
2nd Sep 202111:00 amRNSPrice Monitoring Extension
2nd Sep 20217:00 amRNSLicense Agreement to Evaluate Foralumab with CAR T
20th Aug 20217:00 amRNSTiLS files scheme for a corporate reorganisation
17th Aug 20217:00 amRNSArticle Publication on Foralumab in COVID Patients
16th Aug 20216:11 pmRNSTLSA to Present at the Q3 Virtual Investor Summit
3rd Aug 20214:41 pmRNSSecond Price Monitoring Extn
3rd Aug 20214:35 pmRNSPrice Monitoring Extension
8th Jul 202112:19 pmRNSADS Ex-Dividend Date Scheduled for July, 09 2021
2nd Jul 202112:30 pmRNSDistribution Dates for shares and ADRs in Accustem
2nd Jul 202112:30 pmRNSDistribution Dates: shares and ADRs in Accustem
30th Jun 202111:36 amRNSDr Howard Weiner on Bloomberg at 1.50pm ET today
25th Jun 202110:40 amRNSResult of Annual General Meeting
23rd Jun 20217:00 amRNSP2 Trial with foralumab on Severe COVID19 Patients
21st Jun 20217:08 amRNSAppointment of VP of Regulatory Affairs
17th Jun 20217:00 amRNSTiziana Applies for Grant from UK-CTAP
2nd Jun 20217:00 amRNSNotice of AGM
26th May 20217:00 amRNSSignificant Immunomodulation effects on Biomarkers
25th May 20217:00 amRNSTrial Initiation in a SPMS Patient with Foralumab
21st May 20217:00 amRNSDirector/PDMR Dealing
18th May 202112:18 pmRNSAmended - Final Results
18th May 202111:08 amRNSFinal Results
7th May 20217:00 amRNSTLSA interview on Bloomberg TV on 8th May 2021
5th May 20217:45 amRNSTLSA Strategic Initiative with Takanawa Japan K.K.
27th Apr 20217:00 amRNSB. Riley Virtual Neuroscience Investor Conference
13th Apr 202112:00 pmRNSTiziana Announces Plans to List Accustem in US
30th Mar 20214:41 pmRNSSecond Price Monitoring Extn
30th Mar 20214:36 pmRNSPrice Monitoring Extension
30th Mar 20212:05 pmRNSSecond Price Monitoring Extn
30th Mar 20212:00 pmRNSPrice Monitoring Extension
30th Mar 20211:00 pmRNSFDA Allows Foralumab Treatment for a SPMS Patient

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.